Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
Open accessAbstract
Background: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms. Methods: 50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed. Results: Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid. Conclusions: Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In vivo, MPTP-treated mice receiving propionate show better performance in the stepping test, cylinder test and whisker test.
“in vivo, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; a prodrug of the neurotoxin MPP+)-treated mice receiving propionate show a better performance in the stepping test, cylinder test and whisker test, in line with previous data [109,110]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070 · see citing works
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219 · see citing works
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781 · see citing works
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622 · see citing works
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614 · see citing works
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · see citing works
Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.04.003 · Cited by 1,284 · see citing works
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · see citing works
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159 · see citing works
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · see citing works
Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota
Chen, T., Long, W., Zhang, C., Liu, S., Zhao, L., & Hamaker, B. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-02995-4 · Cited by 608 · see citing works
Self-citationMicrobiome–host systems interactions: protective effects of propionate upon the blood–brain barrier
Hoyles, L., Snelling, T., Umlai, U.-K., Nicholson, J. K., Carding, S. R., Glen, R. C., & McArthur, S. (2018) · Microbiome · doi:10.1186/s40168-018-0439-y · Cited by 591 · see citing works
Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409 · see citing works
Self-citationFernández, J., Redondo-Blanco, S., Gutiérrez‐del‐Río, I., Miguélez, E. M., Villar, C. J., & Lombó, F. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.06.032 · Cited by 373 · see citing works
Microbiota composition and metabolism are associated with gut function in Parkinson's disease
Cirstea, M. S., Yu, A. C., Golz, E., Sundvick, K., Kliger, D., Radisavljevic, N., Foulger, L. H., Mackenzie, M., Huan, T., Finlay, B. B., et al. (2020) · Movement Disorders · doi:10.1002/mds.28052 · Cited by 326 · see citing works
Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes
Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Swanson, P. D., & Checkoway, H. (2003) · Neurology · doi:10.1212/01.wnl.0000068021.13945.7f · Cited by 268 · see citing works
Wu, M., Tian, T., Mao, Q., Zou, T., Zhou, C., Xie, J., & Chen, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01038-3 · Cited by 235 · see citing works
Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., et al. (2021) · Microbiome · doi:10.1186/s40168-020-00988-6 · Cited by 231 · see citing works
Self-citationBaldini, F., Hertel, J., Sandt, E., Thinnes, C. C., Neuberger-Castillo, L., Pavelka, L., Betsou, F., Krüger, R., Thiele, I., Aguayo, G., et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00775-7 · Cited by 224 · see citing works
Vascular Degeneration in <scp>P</scp>arkinson's Disease
Guan, J., Pavlovic, D., Dalkie, N., Waldvogel, H. J., O'Carroll, S. J., Green, C. R., & Nicholson, L. F. B. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00628.x · Cited by 191 · see citing works
Ren, T., Gao, Y., Qiu, Y., Jiang, S., Zhang, Q., Zhang, J., Wang, L., Zhang, Y., Wang, L., & Nie, K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00137 · Cited by 173 · see citing works
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162 · see citing works
Nair, A. T., Ramachandran, V., Joghee, N. M., Shanish Antony, A., & Ramalingam, G. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17105 · Cited by 156 · see citing works
Toward Understanding Microbiome-Neuronal Signaling
Jameson, K. G., Olson, C. A., Kazmi, S. A., & Hsiao, E. Y. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.03.006 · Cited by 150 · see citing works
Plasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease
Shin, C., Lim, Y., Lim, H., & Ahn, T. (2020) · Movement Disorders · doi:10.1002/mds.28016 · Cited by 116 · see citing works
Fu, X., Wang, Y., He, X., Li, H., Liu, H., & Zhang, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01284-w · Cited by 74 · see citing works
Self-citationSurvey of health status and complications among propionic acidemia patients
Peña, L., & Burton, B. K. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35387 · Cited by 70 · see citing works
The serum lipid profile of Parkinson's disease patients: a study from China
Guo, X., Song, W., Chen, K. G., Chen, X., Zheng, Z., Cao, B., Huang, R., Zhao, B., Wu, Y., & Shang, H. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.979288 · Cited by 68 · see citing works
Song, W., Guo, X., Chen, K., Chen, X., Cao, B., Wei, Q., Huang, R., Zhao, B., Wu, Y., & Shang, H. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.10.005 · Cited by 67 · see citing works
Pettenuzzo, L. F. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00856-0 · Cited by 62 · see citing works
Can the gut be the missing piece in uncovering PD pathogenesis?
Chapelet, G., Leclair‐Visonneau, L., Clairembault, T., Neunlist, M., & Derkinderen, P. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.11.014 · Cited by 59 · see citing works
Increased Added Sugar Consumption Is Common in Parkinson's Disease
Palavra, N. C., Lubomski, M., Flood, V. M., Davis, R. L., & Sue, C. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.628845 · Cited by 55 · see citing works
Wei, Q., Wang, H., Tian, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075743 · Cited by 52 · see citing works
Ostendorf, F., Metzdorf, J., Gold, R., Haghikia, A., & Tönges, L. (2020) · Molecules · doi:10.3390/molecules25112502 · Cited by 46 · see citing works
A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease
Mulak, A. (2018) · Movement Disorders · doi:10.1002/mds.27304 · Cited by 45 · see citing works
Lobzhanidze, G., Lordkipanidze, T. G., Zhvania, M. G., Japaridze, N. J., MacFabe, D. F., Pochkidze, N., Gasimov, E. K., & Rzayev, F. (2019) · Micron · doi:10.1016/j.micron.2019.102732 · Cited by 45 · see citing works
Dietary Intake of Parkinson's Disease Patients
Baert, F., Matthys, C., Mellaerts, R., Lemaître, D., Vlaemynck, G., & Foulon, V. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00105 · Cited by 34 · see citing works
Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran.
Saedi, S., Hemmati-Dinarvand, M., Barmaki, H., Mokhtari, Z., Musavi, H., Valilo, M., Mota, A., & Mahjoub, S. (2021) · PubMed Central · doi:10.22088/cjim.12.2.155 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [15]Group of Parkinson's Disease and Movement Disorders NBoCMAPCoPsDaMDoNBoCPA Diagnostic criteria of Parkinson's disease in China (2016 edition) Chin J Neurol 2016 49 4 268 271 10.3760/cma.j.issn.1006-7876.2016.04.002 · DOI
Cited by
Sorted by citations
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
Regulation of microglial physiology by the microbiota
Cook, J., & Prinz, M. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2125739 · Cited by 49 · see citing works
Guo, X., Tang, P., Hou, C., Chong, L., Zhang, X., Liu, P., Chen, L., Liu, Y., Zhang, L., & Li, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.875101 · Cited by 19 · see citing works
Self-citation
- Authors
- Wu, G., Jiang, Z., Pu, Y., Chen, S., Wang, T., Wang, Y., Xu, X., Wang, S., Jin, M., Yao, Y., Liu, Y., Ke, S., & Liu, S.
- Affiliations
- Wenzhou Medical University (CN)
- Shaoxing University (CN)
- Corresponding author
- Ke, Shaofa
- Liu, Suzhi
- Venue
- BMC Neurology
- Published
- 2022-01-07
- Volume
- 22
- Issue
- 1
- Pages
- 13-13
- ISSN
- 1471-2377 (ISSN-L)
- PMC
- PMC8740341
- OpenAlex
- W4205973174
- Cited by
- 67
- References
- 38
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 16 · 2023: 8 · 2022: 15
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- BMC Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, short-chain fatty acids, propionic acid, gut microbiota, motor symptoms, non-motor symptoms, cognitive function, depression, heptanoic acid, butyrate, hexanoic acid, trihexyphenidyl, tizanidine, enteric nervous system
- MeSH terms
- Gastrointestinal Microbiome, Cognition, Fatty Acids, Volatile, Humans, Parkinson Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
